Home › Small Cell Lung Cancer › Massachusetts
Small Cell Lung Cancer clinical trials in Massachusetts
22 studies for Small Cell Lung Cancer are looking for participants at sites in Massachusetts.
Cities in Massachusetts
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- Dana Farber Cancer Institute, Boston
RecruitingPhase 1
Ages 19 and older · All sexes · Updated Sep 28, 2026 · NCT06586957Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
- Tufts Medical Center, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06047379A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
- Dana-Farber Cancer Institute /ID# 277732, Boston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT07155174A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
- Dana-Farber Cancer Institute /ID# 279690, Boston
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT07365241Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
- Massachusetts General Hospital, Boston
RecruitingPhase 1
Ages 18 to 100 · All sexes · Updated Sep 22, 2026 · NCT07006727Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT05983432The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Sep 15, 2026 · NCT04585750A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
- Dana Farber Cancer Institute ( Site 1105), Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT06780137AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
- Avenzo Therapeutics Recruiting Site, Boston
RecruitingPhase 1/2
Ages 18 to 75 · All sexes · Updated Sep 4, 2026 · NCT07038343Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
- Beth Israel Lahey Health - Lahey Hospital & Medical Center (LHMC), Lahey Clinic Medical Center, Burlington
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 1, 2026 · NCT06712355Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
- Dana Farber Cancer Institute, Boston
RecruitingPhase 1/2
Ages 18 to 100 · All sexes · Updated Aug 27, 2026 · NCT06726148A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT06095505A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- Massachusetts General Hospital Cancer Center, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 11, 2026 · NCT05592626A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 6, 2026 · NCT06203210Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer
- Massachusetts General Hospital, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 24, 2026 · NCT06931626A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
- Beth Israel Deaconess Medical Center, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 22, 2026 · NCT06131840A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 15, 2026 · NCT05652686Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer
- Dana Farber Cancer Institute, Boston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jun 26, 2026 · NCT07149363A Study of LY4175408 in Participants With Advanced Cancer
- Massachusetts General Hospital, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 23, 2026 · NCT07046923Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study
- Tufts Medical Center, Boston
- Lahey Hospital and Medical Center, Burlington
- Lahey Medical Center-Peabody, Peabody
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Mar 30, 2026 · NCT06769126Biology of Young Lung Cancer Study: The YOUNG LUNG Study
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Brigham and Women's Hospital, Boston
- and 1 more
RecruitingObservational study
Ages 15 and older · All sexes · Updated Oct 29, 2025 · NCT05265429DNA Analysis of Blood and Tissue from Patients with Lung Cancer
- Massachusetts General Hospital, Boston
- Harvard School of Public Health, Boston
RecruitingObservational studyHealthy volunteers welcome
Ages 18 to 120 · All sexes · Updated Nov 29, 2024 · NCT00471978From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.